SACT 1
Alternative Names: SACT-1Latest Information Update: 28 Jan 2025
At a glance
- Originator Aptorum Group
- Class Antineoplastics; Small molecules
- Mechanism of Action Cell death stimulants; N-myc proto-oncogene protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
- No development reported Colorectal cancer; Neuroblastoma; Triple negative breast cancer
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for phase-I development in Neuroblastoma(In volunteers) in Hong Kong (PO)
- 28 Jan 2025 No recent reports of development identified for preclinical development in Colorectal-cancer in Hong Kong (PO)
- 28 Jan 2025 No recent reports of development identified for preclinical development in Triple-negative-breast-cancer in Hong Kong (PO)